Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.
Article Details
- CitationCopy to clipboard
Toth C
Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.
Ther Adv Drug Saf. 2014 Feb;5(1):38-56. doi: 10.1177/2042098613505614.
- PubMed ID
- 25083261 [ View in PubMed]
- Abstract
Used mainly for the management of neuropathic pain, pregabalin is a gabapentinoid or anticonvulsant that was initially developed as an antiepileptic agent. After more than a decade of experience with pregabalin, experience and studies have shown that the adverse effect profile of pregabalin is well tolerated for the management of neuropathic pain and other conditions. Its use is associated with benign central nervous system and systemic adverse effects, and there are very limited metabolic, idiosyncratic or known teratogenic adverse effects. Along with its efficacy in particular neuropathic pain conditions, pregabalin's safety led it to be one of the first pharmacotherapies considered for the management of neuropathic pain. This review discusses the use of pregabalin as well as its potential adverse effects, including the most commonly noted features of sedation, dizziness, peripheral edema and dry mouth. Although other adverse effects may occur, these appear to be uncommon. The review also discusses the clinical implications of pregabalin's use for the clinician.
DrugBank Data that Cites this Article
- Drugs
- Drug Reactions
Reaction Details - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwarePioglitazonePregabalin The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Pioglitazone. RosiglitazonePregabalin The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Rosiglitazone. TroglitazonePregabalin The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Troglitazone.